Mucinex DM 12 Hr Relief Tablets, 40ct, 600 mg Guaifenesin, 30 mg Dextromethorphan HBr, Controls Cough and Thins & Loosens Mucus That Causes Cough & Ch
Are you searching for reliable cough and cold medicine for adults? Look no further than Mucinex DM 12hr - a powerful expectorant & cough suppressant. Featuring a robust 600 mg of guaifenesin and 30 mg of dextromethorphan HBr, this top-notch chest congestion & cough medicine is here to provide effective symptom relief from bothersome excess mucus and persistent cough. When the cold and flu season hits, trust Mucinex for cough and cold symptom relief for adults. Our original bi-layer tablet provides immediate and extended-release and lasts up to 12 hours.
COUGH & COLD MEDICINE FOR ADULTS: Mucinex DM 12 hr expectorant & cough suppressant packs a powerful punch with 30 mg dextromethorphan HBr & 600 mg guaifenesin extended release tablets
EXCESS MUCUS RELIEF: Powerful multi-symptom relief; Mucinex DM 12hr lasts up to 12 hours, provides relief for your chest congestion and makes coughs more productive
EXPECTORANT FOR ADULTS: Mucinex DM helps clear lungs of excess mucus and phlegm; Say goodbye to chest congestion and cough, say hello to excess mucus relief with our original bi-layer tablets
EXTENDED RELEASE GUAIFENESIN: Experience long-lasting symptom relief with Mucinex DM 12hr extended-release 600 mg guaifenesin and 30 mg dextromethorphan HBr tablets
TRUSTED BRAND: Mucinex is the #1 Cough & Cold Brand Doctor's Trust* and is also the #1 Pharmacist Recommended OTC Expectorant**; Get the brand that doctors trust and recommend
COLD AND FLU MEDICINE FOR ADULTS: For powerful cough, cold, and flu multi-symptom relief, check out our range of Mucinex Fast-Max cold and flu medicines; Beat cold and flu symptoms with confidence
FSA & HSA Eligible: Save Up to 30%; Cover out-of-pocket expenses with pre-tax dollars; Product eligibility may vary by plan, check with your benefits administrator to determine which expenses are eligible before you shop
*IQVIA using ProVoice Survey, August 2023; **U.S. News & World Report/Pharmacy Times 2023-2024
